Xeltis Set To Begin Human Trials Of Endogenous Tissue Pulmonary Valve
This article was originally published in Clinica
A feasibility trial of Xeltis’ PV-001 bioabsorbable cardiac pulmonary valve, based on the company’s unique Endogenous Tissue Restoration technology, will begin this summer at four to six centers in Europe, Xeltis CEO Laurent Grandidier told Clinica.
You may also be interested in...
Transcatheter aortic valve replacement pioneer Martin Leon discussed what is coming down the pike for technologies in the TAVR and heart valve device space at the recent Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego. Here is a run-down of what he highlighted, including AI-driven technologies that promise to improve patient access and outcomes. This is the first of a two-part series focusing on innovations in interventional cardiology.
Medtech Insight's Clinical Corner highlights recent R&D news and developments in ongoing clinical trials of early, late-stage and approved medical devices. This installment includes news on Abbott's Xience drug-eluting coronary stents, Xeltis' bioabsorbable devices for congenital heart defects, NeuroMetrix's Quell pain therapy, and CytoSorbents' blood purifier to treat inflammation in surgery patients.
The $250m deal adds A&E Medical’s sternal sutures, cable systems, and rigid fixation systems to Zimmer Biomet’s Dental, Spine & Craniomaxillofacial and Thoracic business.